The phar­ma world's cham­pi­on patent wall builder is called out for their 'drip-feed' strat­e­gy to safe­guard the next megablock­buster fran­chise

By all ac­counts, Ab­b­Vie holds the ti­tle as a mas­ter builder of patent walls. Its work on Hu­mi­ra has been both leg­endary and ex­tra­or­di­nar­i­ly con­tro­ver­sial, en­cir­cling a cash cow that can be milked with­out any gener­ic ri­vals butting in un­til 2023 — as new and bet­ter drugs come along to out­per­form the copy­cats to come.

And now a group of pa­tient ad­vo­cates at I-MAK say Ab­b­Vie is deep in­to build­ing its sec­ond high se­cu­ri­ty patent perime­ter around Im­bru­vi­ca — the next Hu­mi­ra in the Ab­b­Vie port­fo­lio.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE